StockWatch: MacroGenics Shares Crater after Trial Deaths
MacroGenics president and CEO Scott Koenig, MD, PhD MacroGenics (MGNX) shares cratered 77% on Friday, a day after the company acknowledged the deaths of five patients—three of them potentially treatment-related—in the company’s Phase II TAMARACK trial ( …